EP2274418B1 - Human host cell for producing recombinant proteins with high quality and quantity - Google Patents

Human host cell for producing recombinant proteins with high quality and quantity Download PDF

Info

Publication number
EP2274418B1
EP2274418B1 EP09729465.6A EP09729465A EP2274418B1 EP 2274418 B1 EP2274418 B1 EP 2274418B1 EP 09729465 A EP09729465 A EP 09729465A EP 2274418 B1 EP2274418 B1 EP 2274418B1
Authority
EP
European Patent Office
Prior art keywords
cell
cells
human
derived
ebna1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09729465.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2274418A4 (en
EP2274418A2 (en
Inventor
Hyunjoo Lee
Jongmook Kim
Minseok Chang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celltrion Inc
Original Assignee
Celltrion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltrion Inc filed Critical Celltrion Inc
Publication of EP2274418A2 publication Critical patent/EP2274418A2/en
Publication of EP2274418A4 publication Critical patent/EP2274418A4/en
Application granted granted Critical
Publication of EP2274418B1 publication Critical patent/EP2274418B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids

Definitions

  • the present invention relates to a human host cell for producing recombinant proteins with high quality and quantity, and more particularly, to a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell , by using genetic engineering techniques, wherein the human host cell has stable desired characteristics to be efficiently used for production of heterologous recombinant proteins.
  • recombinant protein-based pharmaceuticals for human use have been produced using non-human mammalian cells, for example, Chinese hamster ovary (CHO) cells, mouse melanoma (NSO) cells, and mouse hybridoma (SP2/0) cells.
  • CHO Chinese hamster ovary
  • NSO mouse melanoma
  • SP2/0 mouse hybridoma
  • human cell lines for the production of therapeutic recombinant proteins, for example, the production of activated protein C (Xigris) using human embryonic kidney 293 cells (Eli Lylly, 2001), the production of interferon-beta using Namalwa cells (Wellcome Research Laboratory, 1999), the production of truncated recombinant factor VIII and a variety of antibodies by HKB11 cells ( Cho et al., 2003, Biotech.
  • U.S. Patent No. 6,136,599 and Korean Patent No. 627,753 discloses the use of human host cells, HKB11 cells to produce proteins which are difficult to express in CHO cells ( Cho et al., 2003, Biotech. Prog 19:229-232 ) ( Cho and Chan, 2002, Biomedical Science 9:631-638 ).
  • U.S. Patent No. 6,358,703 B1 and Korean Patent No. 616,028 discloses a method of producing truncated recombinant factor VIII by HKB 11 cells.
  • the HKB cell is a cell line derived from HH514-16 and includes a genome of Epstein Barr virus (EBV) which is deficient in B-cell immobilization and virus production ( Rabson et al., 1983, PNAS USA 87:3660-3664 ).
  • EBV Epstein Barr virus
  • the HKB cells show characteristics such as high-density growth, high transfection efficiency, and simple MTX-induced amplification, massive secretion of target proteins, and extinction of IgM expression, which are suitable for producing therapeutic proteins.
  • EBV tended to be lost from the HKB cell during the cultivation of the cells ( Chang et al., 2002, J Virol. 76:3168-3178 ). This tendency indicates that the HKB may become free of EBV, thereby failing to preserve various beneficial properties for effective expression of heterologous genes.
  • An object of the present invention is to provide a new human host cell line generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, with an Epstein-Barr virus (EBV) genome inserted into its chromosomes .
  • EBV Epstein-Barr virus
  • Another object of the present invention is to provide a use of the human host cell for producing recombinant proteins.
  • a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell , with an Epstein-Barr virus (EBV) genome inserted into its chromosomes .
  • EBV Epstein-Barr virus
  • a human host cell is generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, with an Epstein-Barr virus (EBV) genome inserted into its chromosomes.
  • EBV Epstein-Barr virus
  • the human embryonic kidney-derived cell may include a human embryonic kidney cell, a cell derived from a human embryonic kidney cell, a cell derived from another cell of human embryonic kidney origin, and a cell resulting from mitotic division of any of the cells mentioned above.
  • 'derived from' is intended to include, but is not limited to, normal mitotic cell division and processes such as transfections, cell fusions, or other genetic engineering or cell biology techniques used to alter cells or produce cells with new characteristics.
  • the human embryonic kidney-derived cell may be a 293 derived cell, and preferably, a 293 cell. The 293 cell exhibits high transfection efficiency and a high level of protein productivity but aggregation occurs in a serum-free suspension culture.
  • the human B-cell-derived cell with the EBV genome inserted in chromosomes may become free of EBY, thereby failing to preserve various beneficial properties for effective expression of heterologous genes.
  • An object of the present invention is to provide a new human host cell line generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, with an Epstein-Barr virus (EBY) genome inserted into its chromosomes .
  • EY Epstein-Barr virus
  • Another object of the present invention is to provide a use of the human host cell for producing recombinant proteins.
  • a human host cell generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, with an Epstein-Barr virus (EBY) genome inserted into its chromosomes, wherein the human embryonic kidney-derived cell is a 293 cell and the human B-cell-derived cell is a Namalwa cell and wherein the human host cell i) constitutively expresses EBNA1 proteins; ii) does not express IgM proteins; iii) continuously generates glycosylation profiles similar to those of humans; and iv) expresses BALF1, but does not express BHRF1, wherein the human host cell is F2N78 deposited under KCTC Accession Number: KCTC 11309BP.
  • EBY Epstein-Barr virus
  • a human host cell is generated from fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell, with an Epstein-Barr virus (EBY) genome inserted into its chromosomes.
  • EY Epstein-Barr virus
  • the human embryonic kidney-derived cell may include a human embryonic kidney cell, a cell derived from a human embryonic kidney cell, a cell derived from another cell of human embryonic kidney origin, and a cell resulting from mitotic division of any of the cells mentioned above.
  • 'derived from' is intended to include, but is not limited to, normal mitotic cell division and processes such as transfections, cell fusions, or other genetic engineering or cell biology techniques used to alter cells or produce cells with new characteristics.
  • the human embryonic kidney-derived cell may be a 293 derived cell, and preferably, a 293 cell. The 293 cell exhibits high transfection efficiency and a high level of protein productivity but aggregation occurs in a serum-free suspension culture.
  • the human B-cell-derived cell with the EBY genome inserted in chromosomes may according to the current embodiment which has useful properties of both the human embryonic kidney-derived cell and the human B-cell-derived cell, a process of genotypic selection of clones having the useful properties of both cells needs to be performed after the fusion of the cells. Since the human embryonic kidney-derived cell, i.e., the 293 cell, is HAT-resistant and G418-sensitive, the human B-cell-derived cell, for example the Namalwa cell, which is HAT-sensitive and G418-resistant is chosen as the fusion partner for the human embryonic kidney-derived cell.
  • the 293 cell and the Namalwa cell are used to develop a new human host cell generated from the fusion of the human embryonic kidney-derived cell and the human B-cell-derived cell.
  • a Namalwa cell line is cultured in a culture medium supplemented with fetal bovine serum (FBS) and 6-thioguanine in order to derive the Namalwa cell, which is HAT-sensitive, as a partner for fusion with the 293 cell.
  • FBS fetal bovine serum
  • 6-thioguanine fetal bovine serum
  • Sensitivity of the Namalwa cell to a HAT-containing culture medium was measured while increasing the concentration of 6-thioguanine for a selection period of several months.
  • a HAT-sensitive Namalwa cell population is transfected with pSV2neo plasmid, and cell population having resistance to G418 is selected to be used as a fusion partner of the 293 cell. Then, fusion of the 293 cell and the HAT-sensitive Namalwa cell is carried out according to a method of using polyethylene glycol (PEG) disclosed in Kennett RH. Cell fusion. Methods Enzymol 58:345-359; 1979 . However, the cell fusion is not limited to the method and may be performed according to methods commonly used in the art.
  • PEG polyethylene glycol
  • the human host cell according to an embodiment of the present invention generated from the fusion of the 293 cell and the Namalwa cell is designated as to F2N ( F used cell of 2 93 and N amalwa). It is expected that the EBV genome is not lost from the F2N cell during a long-term culture since the EBV genome exists integrated into chromosomes of the F2N, unlike HKB cells which have similarity in other features to F2N cells.
  • F2N clones are selected and cultured in a serum free suspension culture medium for longer than 1 year.
  • the expression of EBNA1 is observed in all of the cell population cultured in the serum free suspension culture medium for longer than 1 year (See FIGS. 5 and 6 ), which demonstrates that the EBV genome is not lost from the F2N cell even though the F2N cell is cultured for a long period of time.
  • the cells of F2N clones are transfected with a pCT132 vector (See FIG. 3 ) expressing IgG, and the transfectants are analyzed using an enzyme-linked immunosorbent assay (ELISA) to evaluate antibody production efficiency (See FIGS. 4A to 4C ).
  • ELISA enzyme-linked immunosorbent assay
  • the transfection efficiency of the F2N cell is higher than that of the 293 cell.
  • KCTC Korean Collection for Type Cultures
  • KCTC11309BP Korean Research Institute of Bioscience and Biotechnology
  • RT-PCR reverse transcription-polymerase chain reaction
  • the human host cell continuously expresses EBNA1 protein, expresses enzymes involved in generating glycosylation profiles similar to those of human, and does not express an IgM protein.
  • the human host cell provides stable expression of EBNA1.
  • EBNA1 is a gene having a size of about 3 kb and is an essential element for autonomous replication of oriP expression vector in cells. If EBNA1 exists in cis or in trans with the oriP expression vector in cells, the oriP expression vector may be normally replicated in human cells. However, if EBNA1 does not separately exist from the oriP expression vector (in trans), but exists in the oriP expression vector (in cis), the vector DNA may not be easily handled because the expression vector is too large and all genes including the EBNA1 gene may not be efficiently transferred into the cells and expressed.
  • the oriP plasmid since the EBNA1 protein is constitutively expressed from the EBV genome integrated into chromosomes of the F2N78 cell, the oriP plasmid is not required to have the EBNA1 gene on the vector construction. Thus, the oriP expression vector may be efficiently handled, and genes contained in the vector may be easily expressed.
  • the human host cell according to an embodiment of the present invention also constitutively expresses enzymes related to glycosylation profiles similar to those of humans. Since proteins produced from the human host cell according to an embodiment of the present invention have glycosylation profiles similar to those of humans, the proteins may have lower in vivo immunogenicity and longer in vivo half-life than the proteins produced from non-human cells such as CHO cells, thereby improving efficacy of protein-based pharmaceuticals.
  • the human host cell of an embodiment to of the present invention does not express the IgM protein which is expressed in the Namalwa cell.
  • the human host cell according to an embodiment of the present invention has essential features for producing a therapeutic recombinant monoclonal antibody.
  • the F2N78 cell was treated with different concentrations of sodium butyrate.
  • sodium butyrate increases the expression of genes regulated by a CMV- or SV40- promoter during the cell cultivation ( Lee et al., 1993, Cell 72:73-84 , Cockett et al., 1990, Bio/technology 8:662-667 , Chang et al., 1999, Free Rad Res 30:85-91 , and Gorman et al., 1983, Nucl Acid Res 11:7631-7648 ).
  • F2N78 cells according to an embodiment of the present invention shows decrease in apoptosis even in the treatment of sodium butyrate and in some cases, higher growth rate than the control (F2N78 treated with 0 mM sodium butyrate).
  • Namalwa cell as a control, shows decrease in cell viability and inhibition in cell growth in all conditions after the treatments of sodium butyrate, while 293 cell shows apoptosis when exposed to high concentration of sodium butyrate (See FIGS. 9A to 9D ).
  • BHRF1 and BALF1 which are viral bcl-2 homolog genes contained in the EBV genome.
  • BHRF1 was expressed in Namalwa cells both untreated and treated with sodium butyrate.
  • BHRF1 was not expressed in the F2N78 cells either untreated or treated with sodium butyrate.
  • BALF1 was expressed in both the Namalwa cell and the F2N78 cell regardless of the treatment with sodium butyrate. Both BHRF1 and BALF1 were not expressed in the 293 cell, as a control.
  • the human host cell according to an embodiment to of the present invention shows anti-apoptotic activity when cultured in the presence of sodium butyrate.
  • This invention indicates that the human host cell according to an embodiment to of the present invention may also have resistance to naturally-occurring apoptosis during a long-term batch culture even when sodium butyrate is not added to the culture medium.
  • Two antibody producing cell lines generated from CHO and F2N78 were compared to identify antibody productivity from the cells when treated with sodium butyrate.
  • the cell growth rate of the CHO-derived clone treated with sodium butyrate was reduced by 50%, and the productivity of the CHO-derived clone was doubled when compared with a control which was not treated with sodium butyrate (See FIG. 11 ).
  • the cell growth rate of the F2N78-derived clonel treated with sodium butyrate was increased by up to 2 folds, and the productivity of the F2N78-derived clone was increased by 4 to 5 times when compared with a control which was not treated with sodium butyrate (See FIG. 12 ).
  • the above described results indicate that the anti-apoptosis of the F2N78 cell treated with sodium butyrate influences the increase in productivity of antibodies.
  • the F2N78 cells were transfected with two different oriP expression vectors, pCT132 and pCT125 and then.antibody productivities were compared. While the pCT125 includes an EBNA1 coding sequence in the plasmid, the pCT132 does not include the EBNA1 coding sequence in the plasmid. As shown in FIG. 7 , cells transfected with the pCT132 exhibits comparable or higher antibody productivity when compared with cells transfected with the pCT125. In general, it is advantageous to use a transient transfection to produce a small amount of protein required in the process of new drug development.
  • the human host cell constitutively expresses EBNA1
  • the cell may be suitably used for the new drug development based on the transient transfection using an expression vector without EBNA1 gene such as the pCT132 expression vector.
  • the human host cell may be used to produce recombinant proteins.
  • the human host cell may be genetically engineered to express a variety of recombinant proteins.
  • the recombinant proteins may include human therapeutic recombinant proteins, for example, therapeutic monoclonal antibodies, and therapeutic recombinant proteins other than the monoclonal antibodies.
  • the present invention provides a human host cell generated from a somatic cell fusion of a human embryonic kidney-derived cell and a human B-cell-derived cell with an Epstein-Barr virus (EBV) genome integrated into its chromosomes.
  • EBV Epstein-Barr virus
  • proteins for research may be produced in a short period of time, and heterologous recombinant protein-based pharmaceuticals for human use may be produced with high quantity and quality.
  • FIG. 3 illustrates cleavage maps of expression vectors used herein.
  • Electrophoration and a cationic polymer-based method were used for transfection.
  • Electroporation Logarithmically growing 3x10 6 cells were resuspended in 300 ⁇ l of a RPMI 1640 medium containing 12 ⁇ g of a plasmid pSV2neo vector (2 ⁇ g) and a vector with a matrix attached region (MAR) sequence (10 ⁇ g). Electroporation was performed using a GenePulse II electrophorator (Bio-Rad) (220V/960 microfarads). Transfectant was suspended in a growth medium and cultured for 72 hours. Then the cells were cultured in a selective medium supplemented with 1 mg/ml G418 and 10% fetal bovine serum (FBS) for about 14 days.
  • FBS fetal bovine serum
  • transfected cells actively grew, while control cells did not grow in the selective media.
  • the transfected cells were selected and further cultured in a selective medium supplemented with 1 mg/ml G418.
  • the existence of a neomycin gene was identified by performing a polymerase chain reaction (PCR) using the neomycin gene specific primers.
  • Cationic polymer-based method LipofectamineTM LTX (Invitrogen, 15338-100) and FreeStyleTM Max (Invitrogen, 16447-100) were used for the transfection according to the manufacturer's instructions.
  • LipofectamineTM LTX reagent cells were seeded in a 6-well plate one day prior to transfection such that the confluence of the cells reached 50 to 80% per well on the day of transfection. 2.5 ⁇ g of DNA and 6.25 ⁇ l of LTX were used to perform the transfection in each well.
  • FreeStyleTM Max reagent transfection was performed in suspension culture.
  • EX-CELL 293 medium For the transfection of suspension culture, cells growing in a serum free medium (FreeStyle 293 Expression medium, Invitrogen, 12338,, hereinafter referred to as FreeStyle 293 medium) or in EX-CELL 293 Serum free medium (Sigma, 14571C, hereinafter referred to as EX-CELL 293 medium), were seeded such that the concentration of the cells were adjusted to 1x10 6 cells per 1 ml on the day of the transfection. The transfection was performed in an OptiPRO SFM II (Invitrogen, 12309) medium with addition of DNA and FreeStyleTM Max reagent in a ratio of 1:1.
  • FreeStyle 293 Expression medium Invitrogen, 12338
  • EX-CELL 293 Serum free medium Sigma, 14571C, hereinafter referred to as EX-CELL 293 medium
  • anti-complement immunoflluroescence (Reedman and Klein, 1973 and Fresen and curse Hausen, 1976) was applied.
  • ACIF anti-complement immunoflluroescence
  • cells were smeared on a slide glass and fixed using methanol at -20°C for 5 minutes.
  • human serum having a high anti-EBNA titer was used to react with the cells.
  • the cells were treated with human complement (serum protein) to amplify signals form EBNA1, and the EBNA1 dyeing was detected using a fluorescent material-conjugated anti-human complement C3 antibody (FITC-conjugated anti human complement C3 antibody, USBiological, C7850-14C).
  • FITC-conjugated anti human complement C3 antibody USBiological, C7850-14C.
  • the resulting slide was treated with a solution of glycerol and a phosphate buffer in a ratio of 1:1.
  • cells were treated with a fluorescent material-conjugated anti-human IgM antibody (FITC-conjugated affinity-purified goat anti-human IgM, mu chain specific, Sigma, F5384) and a fluorescent material-conjugated anti-human kappa chain (Fluorescein anti-human kappa chain, affinity purified made in goat, Vector, FI-3060) in the same manner as described above.
  • FITC-conjugated affinity-purified goat anti-human IgM, mu chain specific, Sigma, F5384 fluorescent material-conjugated anti-human kappa chain
  • Fluorescein anti-human kappa chain affinity purified made in goat, Vector, FI-3060
  • ⁇ (2,6)ST protein cells were treated with a fluorescent material-conjugated Sambucus nigra lectin (FITC conjugated Sambuicus nigra (Elderberry bark)-SNA-1, EY laboratories, F-2602) in the same manner as described above.
  • FITC conjugated Sambuicus nigra Elderberry bark
  • mRNA was extracted from cells using a RNeasy®Plus Mini kit (Qiagen, 74134), and RT-PCR was performed using a OneStep RT-PCR Kit (Qiagen, 210212).
  • RNeasy®Plus Mini kit Qiagen, 74134
  • RT-PCR was performed using a OneStep RT-PCR Kit (Qiagen, 210212).
  • Table 1 Each of the primer sequences are shown in Table 1 below.
  • the RT-PCR was performed using a GeneAmp PCR system 9700 (Applied Biosystems), and stages and conditions for the RT-PCR were as follows: (i) reverse transcription (1 cycle of 50°C for 30 minutes); (ii) inactivation of reverse transcriptase and cDNA denaturation (1 cycle of 95°C for 15 minutes); (iii) PCR amplification (35 cycles of 94°C for 30 seconds, 52°C for 1 minute, and 72°C for 30 seconds); and (iv) elongation (1 cycle of 72°C for 10 minutes). Products of the RT-PCR were identified using agarose gel electrophoresis. Table 1.
  • the concentration of secreted antibodies was measured using an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • goat anti-human immunoglobulin G(Fc ⁇ ) Jackson ImmunoReserarch, 109-006-098
  • BSA bovine serum albumin
  • 2-fold serial dilutions of the sample were placed in each of the wells on the plate.
  • the plate was incubated at room temperature for 2 hours, and was treated with a peroxidase-labeled goat anti-human ⁇ antibody (Sigma, A5175) for detection.
  • the resultant was incubated at room temperature for 1 hour and reacted with tetramethyl benzidine (TMB), and the reaction was terminated using 1 N HCl.
  • TMB tetramethyl benzidine
  • the human IgG1 lambda purified from myeloma plasma (Sigma, 15029) was used as a standard from a concentration of 250 ng/ml.
  • the concentration of antibodies was measured based on absorbance at 450/570nm using a Spectramax plus 384, Molecular Device.
  • Example 1 Generation of human somatic hybrid cell line by cell fusion
  • Namalwa cell was cultured in RPMI1640 medium supplemented with 10% FBS (Hyclone, SH30070.03) and 6-thioguanine (Sigma, A4660) to generate a HAT(Sigma, H0262)-sensitive and G418(Calbiochem, 345810)-resistant cell as a fusion's partner.
  • FBS Hyclone, SH30070.03
  • 6-thioguanine Sigma, A4660
  • the Namalwa cell was treated with growing concentrations of 6-thioguanine from 5 ⁇ g /ml to 30 ⁇ g /ml, and sensitivity of the cell to a 1x HAT-containing medium was identified.
  • the HAT-sensitive Namalwa cell population was transfected with pSV2neo plasmid, and then cells having resistance to G418 (1.5 mg/ml) were selected to be used as the fusion's partner.
  • the cell fusion was performed using polyethyolene glycol (PEG) according to a method disclosed in Kennett RH (Cell fusion in Methods Enzymol 58:345-359; 1979 ).
  • PEG polyethyolene glycol
  • 293 cells (4x10 6 ) and Namalwa cells (6x10 6 ) in the logarithmic growth phase were washed twice with a calcium (Ca 2+ )- and magnesium (Mg 2+ )-free phosphate buffer, and seeded onto a 6-well plate pre-treated with 5 ⁇ g/ml peanut agglutinin (Sigma, L0881). The 6-well plate was centrifuged at 400 g for 6 minutes (in Beckman AllegraTM X-12R centrifuge).
  • the phosphate buffer was removed from the wells, and the cells in the wells were treated with 2 ml of 40 % polyethylene glycol (Sigma, P7777) for 2 minutes. Cells in one of the wells were not treated with polyethylene glycol as a control. Then, the cells were washed three times with 5 ml of a phosphate buffer supplemented with 5 % dimethyl sulphoxide (DMSO; Sigma, D2650), and washed three times with a phosphate buffer. The cells were treated with a culture medium of a DMEM/F12 medium and a RPMI1640 medium mixed at a ratio of 1:1 supplemented with 15% FBS. The cells were maintained in a CO 2 incubator for 30 minutes.
  • DMSO dimethyl sulphoxide
  • the culture medium was removed, and the cells were treated with a selective medium supplemented with 0.4 mg/ml G418, 0.5x HAT, and 15% FBS, wherein a DMEM/F12 and a RPMI1640 were mixed in equal amounts.
  • the treated cells (1x10 4 ) were seeded in each well of the 96-well plate. After one week, the culture medium was exchanged with the fresh complete selective medium mentioned beforehand. Two weeks post the seeding, a selective medium having 0.8 mg/ml G418, 1x HAT, and 15 % FBS was supplied to the cells. After three weeks from the seeding, it was observed that control cells did not grow, but the fused cells grew.
  • LDC limiting dilution cloning
  • SCC single cell-derived clone
  • F2N 97 single cell-derived clones were obtained, and designated as F2N.
  • the F2N is an individual clone generated from the fusion of the 293 cell and the Namalwa cell.
  • the growth pattern of F2N clones was various, from a loosely attached each other to tightly aggregated patches ( Figure 2 ). All clones were preserved frozen in a nitrogen tank. The transfection efficiency and the expression of EBNA1 and IgM were tested before freezing.
  • IF FIG. 5
  • RT-PCR See FIG. 6
  • IF FIG. 5
  • RT-PCR See FIG. 6
  • IF the expression of EBNA1 was identified using IF and RT-PCR using two different types of primer pairs
  • extinction of Ig-mu expression was identified using IF and RT-PCR, and extinction of Ig-kappa expression was identified using IF
  • GnTIII Campbell and Stanley, 1984
  • ⁇ (2,6)ST which does not exist in CHO cells but in human cells, was identified by IF.
  • a transient transfection has been used to produce, in a short period of time, protein required to develop a new drug.
  • a F2N78 cell and a 293 cell suspension-cultured in FreeStyle 293 medium were transfected with two oriP expression vectors having different structures; pCT132 and pCT125, to compare antibody productivities.
  • pCT125 includes an EBNA1 coding sequence in plasmid, while pCT132 does not contain the EBNA1 coding sequence in plasmid.
  • IgG productivity was similar in the transfected F2N78 with both vectors in repeatedly performed transfections, while IgG production in the transfected 293 with pCT125 was higher than that with pCT132.. Furthermore, the amount of IgG produced by the F2N78 cell transfected with pCT132 (equal to or greater than 25 ⁇ g / ml) was greater than that produced by the 293 cell transfected with pCT125 (15 ⁇ g / ml).
  • the efficiency of IgG production by the pCT132 (wothout EBNA1 gene) in the transfected F2N78 cell was higher than that by the pCT125 (with EBNA1 gene) in the transfected 293 cell.
  • the IgG production by pCT125 was higher than that by pCT132 in 293 cell lacking EBNA1 gene.
  • transfection efficiency of the human host cell according to the present invention is higher than that of the 293 cell line.
  • the treatment of cells with sodium butyrate influences production cell lines in two ways. While the treatment of sodium butyrate increases expression levels of transgenes by hyper-acetylation of the genes, it reduces cell growth rates by inducing apoptosis.
  • CHO, 293, Namalwa, and F2N78 cells which had been adapted to grow in EX-CELL 293, were seeded such that the concentration of the cells was adjusted to 3x10 5 per 1 ml, and were treated with different concentrations of sodium butyrate (0, 1, 2, and 4 mM) on the third day after seeding.
  • the cell number and cell viability of the treated CHO cells rapidly decreased as the concentration of sodium butyrate increased, when compared to non-treated control cells.
  • the cell number and cell viability of the treated Namalwa cells also rapidly decreased in all concentrations of sodium butyrate treated in the similar manner as in the CHO cells.
  • the growth rate and cell viability of the treated 293 cells was not influenced by low concentration of sodium butyrate (1 mM and 2 mM), but the growth rate and cell viability of the 293 cell significantly decreased at a high concentration of sodium butyrate (4 mM).
  • the growth rate and cell viability of the treated F2N78 cells did not decrease under all conditions, but slightly increased at a high concentration of sodium butyrate (4 mM).
  • BHRF1 and BALF1 which are viral bcl-2 homolog genes contained in the EBV genome genes derived from Namalwa cell, were identified using RT-PCR. As shown in FIG. 10 , while only BALF1 was expressed in the F2N78 cells both untreated and treated with sodium butyrate, both BHRF1 and BALF1 were expressed in Namalwa cells. Both of BHRF1 and BALF1 were not expressed in the 293 cell, used as a negative control.
  • the anti-apoptotic cell growth of the F2N78 cell is supported by the fact that BHRF1 is not expressed in the F2N78 cell, even though the F2N78 cell is derived from the Namalwa cell. It has been reported that BALF1 inhibits anti-apoptotic activity of BHRF1 when both BALF1 and BHRF1 are simultaneously expressed ( Marshall et al., 1999, J Virol. 73:5181-5185 ). Thus, the fact that only BALF1 is expressed in the F2N78 cell may explain the anti-apoptotic activity of the F2N78 cell, which was not observed in the Namalwa cells treated with sodium butyrate. However, since both genes are expressed in the Namalwa cell, the anti-apoptotic cell growth may not be observed in the Namalwa cell, unlike in F2N78 cells.
  • CHO#247 is a single cell derived antibody producing clone which was derived from the transfetced CHO after MTX amplification
  • F2N78_Ig is an antibody producing cell line derived from the transfetced F2N78 after selection with puromycin. Cells were seeded and were treated with different concentrations (0, 1, 2, and 4 mM) of sodium butyrate 3 day post seeding.
  • the cell growth rate of the CHO#247 treated with 1 mM of sodium butyrate was reduced by nearly 50% at 5 days post treatment when compared to control culture, however, the antibody productivity was doubled when compared with a control (See FIG. 11 ).
  • the cell growth rate of the F2N78_Ig treated with 4 mM of sodium butyrate was increased by up to 2 times at the late phase of the treatment (4, 5, and 6 days post treatment), and the productivity of the F2N78_Ig was increased by 4 to 5 times when compared with a control (See FIG. 12 ).
  • the effect of sodium butyrate on the F2N78_Ig was maximum with the highest sodium butyrate (4 mM) among tested conditions, while the effect showed the best with 1 mM of sodium butyrate in case of CHO#247.
  • the effect of sodium butyrate on antibody production from F2N78_Ig was higher than that of the CHO#247. This result indicates that anti-apoptotic growth property of the F2N78 observed after a treatment with sodium butyrate could be an additional effects on the production of antibody.
  • EBV genomes exist generally as an episomal state during an EBV life cycle to produce virus particles
  • the Namalwa cell harbors two copies of EBV genomes integrated into the chromosomes ( Henderson et al., 1983, PNAS USA 80:1987-1991 and Rose et al., 2002, J. Clin. Microbiol. 40:2533-2544 ).
  • Such an exceptional form of the EBY genome integrated into chromosomes provides two beneficial properties when such cells are used as a host cell line for the production if therapeutic recombinant proteins.
  • EBY particle can not be produced from such an integrated state in chromosomes and constitutive expression of EBNA1 protein.
  • F2N has the expression of only one viral bcl2 homolog BALF1, not both genes. Namely, the extinction of BHRF1 expression in F2N cells is an unexpected result, therefore, showing an anti-apoptotic growth of the F2N78 cell.
  • the constitutive expression of the EBNA1 gene make it possible to effectively utilize oriP expression vector without EBNA1 gene in it,.
  • the expressions of GnTIII and a(2,6)ST offer the condition for the production of the molecules with more human like glycoprofile.
  • the extinction of lg-mu chain and lg-kappa chain expression also make it possible to utilize F2N cells for the production of recombinant monoclonal antibodies
  • the anti-apoptotic cell growth is very important to increase the production of recombinant proteins.
  • the anti apoptotic cell growth of F2N cells observed when treated with sodium butyrate could be applied to increase the production of the heterologous proteins in conjunction with sodium butyrate during the manufacturing.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
EP09729465.6A 2008-04-12 2009-04-10 Human host cell for producing recombinant proteins with high quality and quantity Active EP2274418B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080033972A KR101005967B1 (ko) 2008-04-12 2008-04-12 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포
PCT/KR2009/001856 WO2009125999A2 (en) 2008-04-12 2009-04-10 Human host cell for producing recombinant proteins with high quality and quantity

Publications (3)

Publication Number Publication Date
EP2274418A2 EP2274418A2 (en) 2011-01-19
EP2274418A4 EP2274418A4 (en) 2013-07-24
EP2274418B1 true EP2274418B1 (en) 2018-10-10

Family

ID=41162409

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09729465.6A Active EP2274418B1 (en) 2008-04-12 2009-04-10 Human host cell for producing recombinant proteins with high quality and quantity

Country Status (6)

Country Link
US (1) US8361790B2 (zh)
EP (1) EP2274418B1 (zh)
JP (1) JP5503636B2 (zh)
KR (1) KR101005967B1 (zh)
CN (1) CN102057038B (zh)
WO (1) WO2009125999A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10165107B2 (en) 2011-10-11 2018-12-25 Samsung Electronics Co., Ltd. Apparatus and method for safe conveyance of notifications and/or alerts to a mobile terminal
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
WO2019151632A1 (ko) 2018-01-31 2019-08-08 (주)셀트리온 중동호흡기증후군 코로나바이러스에 중화활성을 갖는 결합 분자
CN113604425B (zh) * 2021-06-22 2022-10-18 中山康天晟合生物技术有限公司 一种适应无血清培养基环境的wayne293 lvpro细胞及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045849B2 (ja) * 1980-08-25 1985-10-12 林原 健 ヒトエリトロポエチンの製造方法
KR860000897A (ko) 1985-07-04 1986-02-20 원본미기재 로커형 도관만곡기
US5001065A (en) 1987-05-27 1991-03-19 Cetus Corporation Human cell line and triomas, antibodies, and transformants derived therefrom
JPH06277052A (ja) * 1993-03-30 1994-10-04 Kyowa Hakko Kogyo Co Ltd α２，３−シアリルトランスフェラーゼ
US6136599A (en) * 1998-12-10 2000-10-24 Bayer Corporation Human hybrid host cell for mammalian gene expression
US6358703B1 (en) 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Also Published As

Publication number Publication date
CN102057038A (zh) 2011-05-11
CN102057038B (zh) 2013-06-19
WO2009125999A2 (en) 2009-10-15
WO2009125999A3 (en) 2010-01-14
KR101005967B1 (ko) 2011-01-05
KR20090108508A (ko) 2009-10-15
JP2011517566A (ja) 2011-06-16
US20110065184A1 (en) 2011-03-17
JP5503636B2 (ja) 2014-05-28
EP2274418A4 (en) 2013-07-24
US8361790B2 (en) 2013-01-29
EP2274418A2 (en) 2011-01-19
WO2009125999A8 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
JP5826311B2 (ja) 哺乳類遺伝子発現のためのヒトハイブリッド宿主細胞
AU734800B2 (en) Production of a multimeric protein by cell fusion method
JP5432117B2 (ja) 宿主細胞中の組換えタンパク質の発現を増進するための組換え発現ベクター要素（ｒＥＶＥ）
CA1315715C (en) Human cell line and triomas, antibodies, and transformants derived therefrom
EP2274418B1 (en) Human host cell for producing recombinant proteins with high quality and quantity
CN114058625A (zh) 一种cho细胞基因nw_003613781.1内稳定表达蛋白质的位点及其应用
EP2009094B1 (en) Fusion partner cells
Lee et al. Application of a new human cell line, F2N78, in the transient and stable production of recombinant therapeutics
CA1218947A (en) Human hybrid cell lines
JP3415840B2 (ja) 外来蛋白質の産生方法
AU768101B2 (en) Production of a multimeric protein by cell fusion method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101009

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/00 20060101AFI20101221BHEP

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130620

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/22 20060101AFI20130614BHEP

17Q First examination report despatched

Effective date: 20160225

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602009054983

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C12N0005000000

Ipc: C12N0005240000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 5/24 20060101AFI20180607BHEP

INTG Intention to grant announced

Effective date: 20180627

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1051260

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181015

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009054983

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20181010

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1051260

Country of ref document: AT

Kind code of ref document: T

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190110

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190110

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190210

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190210

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20190111

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009054983

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

26N No opposition filed

Effective date: 20190711

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190410

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190430

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20090410

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20181010

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230503

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230206

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20240318

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240321

Year of fee payment: 16